Clinical Research Directory

Inclusion Criteria: Experimental group: Each patient * experiencing a bleeding volume of more than 800 mL * due to surgery or to atony uterine * during an elective or non-emergent caesarean section * secondary post-partum haemorrhage after caesarean section, even if CS has been emergent * after complete information and consent signature. * covered by social security. Reference non-hemorrhagic group: Each patient * experiencing a bleeding volume of strictly less than 800 mL * during an elective or emergent caesarean section * after complete information and consent signature. * covered by social security. Exclusion Criteria: Patient unable to consent (\<18 years old or incapable people and specially protected mentioned in the article L1121-5 to L1121-8) RCP medical contraindication to tranexamic acid such as * Hypersensibility to the product or excipient, * Previous or ongoing arterial or venous thrombosis, * Coagulopathy, except DIC associated with a predominant fibrinolytic profile, * Renal failure, * Previous seizures, * intrathecal or intraventricular administration. Obstetrical contraindication to TA * Severe HELLP syndrome (platelet count \<50 000/m3 or renal failure prior to the caesarean (RIFLE score\>2) Protocol related contraindication to inclusion * Administration of TA before inclusion-Inherited haemorrhagic diseases and low molecular weight heparin within 24 hours before inclusion * Patients who participated in a study on the efficacy of an experimental drug in the two month preceding the caesarean section * Inherited haemorrhagic diseases or low molecular weight heparin within 24 hours before inclusion * Previous inclusion in an interventional trial since the 2 months before CS